279 related articles for article (PubMed ID: 23481262)
1. Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Berasain C
Gut; 2013 Dec; 62(12):1674-5. PubMed ID: 23481262
[No Abstract] [Full Text] [Related]
2. Long-term treatment of hepatocellular carcinoma with sorafenib.
Rombolà F; Spinoso A
Infez Med; 2013 Jun; 21(2):167-8. PubMed ID: 23774984
[No Abstract] [Full Text] [Related]
3. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
[No Abstract] [Full Text] [Related]
4. Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.
Azmi AN; Chan WK; Goh KL
J Dig Dis; 2015 Sep; 16(9):537-40. PubMed ID: 26147446
[No Abstract] [Full Text] [Related]
5. Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma.
Piscaglia F; Salvatore V; Venerandi L
Dig Liver Dis; 2013 May; 45(5):367-8. PubMed ID: 23562444
[No Abstract] [Full Text] [Related]
6. Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.
Tanoglu A; Karagoz E
Asian Pac J Cancer Prev; 2014; 15(2):1063. PubMed ID: 24568452
[No Abstract] [Full Text] [Related]
7. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
8. Education and imaging: Hepatobiliary and pancreatic: Volume-perfusion CT for monitoring therapy for hepatocellular carcinoma.
Grözinger G; Plentz R; Horger M
J Gastroenterol Hepatol; 2013 Mar; 28(3):588. PubMed ID: 23565554
[No Abstract] [Full Text] [Related]
9. Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib.
Gores GJ
Nat Rev Gastroenterol Hepatol; 2014 Nov; 11(11):645-7. PubMed ID: 25245016
[TBL] [Abstract][Full Text] [Related]
10. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
11. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
12. [Treatment of advanced hepatocellular carcinoma].
Kudo M
Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1327-34. PubMed ID: 22863955
[No Abstract] [Full Text] [Related]
13. Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.
Lulla PD; Brammer JE; Bandeali S; Lynch GR
J Gastrointest Cancer; 2013 Mar; 44(1):98-101. PubMed ID: 23054578
[No Abstract] [Full Text] [Related]
14. Treatment of advanced hepatocellular carcinoma: beyond sorafenib.
Meyer T
Lancet Gastroenterol Hepatol; 2018 Apr; 3(4):218-220. PubMed ID: 29533189
[No Abstract] [Full Text] [Related]
15. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
Poullenot F; Bioulac-Sage P; Laumonier H; Saric J; Carteret T; Blanc JF
Acta Oncol; 2014 Mar; 53(3):420-3. PubMed ID: 23713857
[No Abstract] [Full Text] [Related]
16. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
de Stefano G; Iodice V; Farella N
J Gastrointest Cancer; 2015 Dec; 46(4):430-3. PubMed ID: 25894635
[No Abstract] [Full Text] [Related]
17. Immune oncology in hepatocellular carcinoma-hype and hope.
Wörns MA; Galle PR
Lancet; 2017 Jun; 389(10088):2448-2449. PubMed ID: 28434649
[No Abstract] [Full Text] [Related]
18. Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
Chen SC; Chao Y; Yang MH
Am J Gastroenterol; 2017 Apr; 112(4):659-660. PubMed ID: 28381841
[No Abstract] [Full Text] [Related]
19. Letter: The antiviral activity of sorafenib in patients with hepatitis C-related hepatocellular carcinoma.
Ji F; Li Z
Aliment Pharmacol Ther; 2013 Feb; 37(3):372-3. PubMed ID: 23281732
[No Abstract] [Full Text] [Related]
20. Severe adverse skin reaction and desensitization to sorafenib.
Linauskiene K; Malinauskiene L; Vitkauskaite E; Chomiciene A; Blaziene A
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):209-10. PubMed ID: 27372655
[No Abstract] [Full Text] [Related]
[Next] [New Search]